Publikasi Scopus FKUI Terkait Covid-19 Update 13 Desember 2021

Sumantri A.F., Bashari M.H., Tadjoedin H., Atik N.
57435201400;55893976900;57435336400;52063109800;
Risk of coronavirus disease 2019 (COVID-19) infection on leukemia patients: basic science to clinical aspect
2022
Journal of Advanced Pharmacy Education and Research
12
1
38
45
Postgraduate Program, Faculty of Medicine, Padjadjaran University, Bandung, Indonesia; Department of Internal Medicine, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia; Department of Biomedical Sciences, Faculty of Medicine, Padjadjaran University, Bandung, Indonesia; Oncology and Stem Cell Working Group, Faculty of Medicine, Padjadjaran University, Bandung, Indonesia; Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia
Sumantri, A.F., Postgraduate Program, Faculty of Medicine, Padjadjaran University, Bandung, Indonesia, Department of Internal Medicine, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia; Bashari, M.H., Department of Biomedical Sciences, Faculty of Medicine, Padjadjaran University, Bandung, Indonesia, Oncology and Stem Cell Working Group, Faculty of Medicine, Padjadjaran University, Bandung, Indonesia; Tadjoedin, H., Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Atik, N., Department of Biomedical Sciences, Faculty of Medicine, Padjadjaran University, Bandung, Indonesia, Oncology and Stem Cell Working Group, Faculty of Medicine, Padjadjaran University, Bandung, Indonesia
In March 2020, the Coronavirus disease 2019 (COVID-19) pandemic was announced by the World Health Organization (WHO). A novel strain of coronavirus, recently named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) created the disease, which showed symptoms similar to SARS. The virus's bond determines its pathogenesis with its host's cell receptors, mainly the Angiotensin-Converting Enzyme 2 (ACE2). It is a factor of the Renin-Angiotensin System (RAS), that holds a vital function in hematopoiesis of hematologic malignancies. There is mRNA expression of the RAS component, so there is an increase in ACE2 levels in patients with leukemia, primarily the myeloid type. Acute Myeloid Leukemia (AML) malignant blood cells can escape from the immune system through a biochemical mechanism that causes AML cells to deactivate Natural Killer (NK) and cytotoxic lymphoid cells (cytotoxic T cells (CTC). This review article aims to explain the molecular mechanism, including leukemia patients' immune system with COVID-19 and recommendations for patients and hemato-oncologists. © 2022 Journal of Advanced Pharmacy Education & Research | Published by SPER Publication
Ace2; Covid-19; Immune system; Leukemia; Sars-cov
SPER Publications
22493379
Article
Q3
162
22055